Anthem Biosciences reported Q2 FY27 consolidated revenue from operations of INR594 crores, EBITDA of INR330 crores at a 50.6% margin, and PAT of INR211 crores at a 32.04% margin.

3 source passages

First of all, we are pleased to report a robust performance for Q2 FY27, with consolidated revenue from operations going up to INR594 crores for the quarter. The EBITDA was INR330 crores, with EBITDA margins at 50.6%. PBT was INR296 crores, while PAT, that is profit after tax, was INR211 crores, with PAT margins at 32.04%. Open the document at this passage

Jul 22

Earnings call

Q1 2027 earnings call AI summary on its way

May 20

Earnings call

Q4 2026 earnings call AI summary on its way

Feb 5

Earnings call

Q3 2026 earnings call AI summary on its way

Showing 1–4 of 4 documents